Teru Hideshima - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Teru Hideshima's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Teru Hideshima
Verified
Editorial Board, Blood Cancer Journal
Beats
Technology, Health Care, Entertainment , Mental Health , Alzheimer’s , Dementia, Automotive
I don't cover politics, tech and gaming.
Content
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma - Leukemia
By Jooeun Bae, Teru Hideshima, Yu-Tzu Tai, Fabrizio Accardi| Nature Verified AbstractImmune profiling in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM) provides the framework for developing novel immunotherapeutic strategies. Here, we demonstrate decreased CD4+ Th cells, increased Treg and G-type MDSC, and upregulation of immune checkpoints on effector/regulatory and CD138+ cells in MM patients, compared MGUS/SMM patients or healthy individuals.
By Jiye Liu, Teru Hideshima, Lijie Xing, Su Wang| Science Magazine Verified AbstractImmunomodulatory drugs (IMiDs) have markedly improved patient outcome in multiple myeloma (MM); however, resistance to IMiDs commonly underlies relapse of disease. Here, we identify that tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) knockdown (KD)/knockout (KO) in MM cells mediates IMiD resistance via activation of noncanonical nuclear factor κB (NF-κB) and extracellular signal–regulated kinase (ERK) signaling.
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma - Leukemia
By Jooeun Bae, Teru Hideshima, Yu-Tzu Tai, Fabrizio Accardi| Nature Verified AbstractImmune profiling in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM) provides the framework for developing novel immunotherapeutic strategies. Here, we demonstrate decreased CD4+ Th cells, increased Treg and G-type MDSC, and upregulation of immune checkpoints on effector/regulatory and CD138+ cells in MM patients, compared MGUS/SMM patients or healthy individuals.
Company Info
Blood Cancer Journal
Hoboken, New Jersey, United States
'+1 201-748-6000